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Abstract
Background: Monoallelic mutations of the Surfactant Protein C gene (SFTPC) are associated with Interstitial Lung
Disease in children. I73T is the most common mutation, accounting for 30 % of all cases reported.
Case presentation: We describe three patients carrying the same I73T SPC mutation with very different
phenotypes, clinical course (ranging from mild respiratory symptoms to death for respiratory failure) and outcome.
Conclusions: The disease mechanisms associated with SP-C mutations suggest that the combination of individual
genetic background and environmental factors contribute largely to the wide variability of clinical expression.
Infants, children and adults with ILD of unknown etiology should be investigated for SP-C genetic abnormalities.
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Background
The Surfactant Protein C gene (SFTPC, ENGS00000168484)
encodes a 197 aminoacid apoprotein, subsequently
cleaved into the mature Surfactant Protein C (SP-C),
which is incorporated together with specific phospho-
lipids and proteins into lamellar bodies in alveolar type
2 cells, then released via regulated exocytosis in the
gas-liquid interface of the alveolus, playing a critical
role in the modulation of lung mechanics. Lung dis-
eases due to SFTPC mutations are inherited either as
autosomal dominant trait with variable penetrance or
as sporadic disease caused by a de novo single muta-
tion, and were first described in 2001 [1]. These dis-
eases have a broad spectrum of clinical presentations
and manifestations, ranging from lethal neonatal re-
spiratory distress syndrome to adult chronic interstitial
lung disease (ILD). The cellular mechanisms underlying
the pathogenesis of SFTPC mutation-associated ILD
are not completely understood. Very few mutations af-
fecting the mature peptide have been reported in
human, most mutations being located in the C-
terminus residue of the apoprotein. Mutations located
in the BRICHOS domain flanking the C-terminus have
been implicated in protein misfolding response and
apoptosis. In fact, the proSP-C BRICHOS domain plays
an essential chaperone role in preventing the highly
hydrophobic mature SP-C peptide to aggregate in the
endoplasmic reticulum and cause cell death [2, 3]. Con-
versely, non-BRICHOS mutations in the C-terminus
linker domain (I73T, E66K) interfere with autophagic
vacuole formation and maturation, causing a distinct
ultrastructural phenotype with large intracytoplasmic
vacuoles containing unstructured phospholipids [4, 5].
The g.1286 T > C mutation, leading to a substitution of
threonine to isoleucine at codon 73 (I73T), is now rec-
ognized as the most common SP-C mutation, account-
ing for about 30 % of all cases reported [6–9]. We
describe three patients with different clinical presentation,
whose common denominator is the I73T mutation.
Case presentation
Case #1 is a 3 years old term-born girl referred for
persistent cough and dyspnea and intermittently re-
quired oxygen supplementation started one month
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before presentation, and chest CT performed 3 months
after onset showed diffuse ground glass opacities and
subpleural parenchymal micronodules. She is the second
daughter of non-consanguineous healthy parents. Her
sister died in the first year with respiratory insufficiency
of unidentified etiology. The child was in good general
condition. Chest auscultation was unremarkable. Humoral
and cellular immunity testing, sweat tests and genetic ana-
lysis for cystic fibrosis,, cardiac evaluation, abdominal
ultrasound all resulted normal. CT scan confirmed wide-
spread patchy ground glass opacities and subpleural
micronodules, with interstitial thickening. Bronchoscopy
showed normal airways; bronchoalveolar Lavage (BAL)
showed normal cytology and lipid index, negative bacterial
culture, and negative respiratory viral immunofluores-
cence and PCR tests. SFTPC gene sequencing detected
the I73T mutation. Parents, who were both asymptomatic,
were not mutation carriers. The genetic findings are diffi-
cult to interpret, as parental testing suggests a de novo
mutation, but would imply that the sibling died of an un-
related cause. The child was started on hydroxychloro-
quine 5 mg/kg/day per oral (HCQ). Her cough and
dyspnea improved after one week and she was discharged
home on room air. Three months after she was still com-
pletely asymptomatic, and a repeat chest CT was im-
proved, showing disappearance of the ground glass
abnormalities but persistence of micronodules. After six
months we observed a complete recovery of the CT find-
ings. At 3 years of age the child is still on treatment, with
no respiratory symptoms.
Case #2 is a 4 years old male born at term, asymptom-
atic with normal growth and development until he pre-
sented at 6 months of age with a respiratory syncytial
virus (RSV) bronchiolitis, which evolved in acute re-
spiratory distress syndrome (ARDS) requiring surfactant
administration and mechanical ventilation for one week.
Bronchoscopy was normal; lung CT showed ground-
glass attenuations suggestive of ILD. Immunological
screening showed a mild IgA and IgG deficiency. Sweat
test and cystic fibrosis genetic test were normal. The in-
fant was discharged home after one month, on oxygen
and oral methylprednisolone. He was referred to our
center at 12 months,of age. The infant was in poor nu-
tritional status, with a weight <10th percentile. Clinically,
he had intercostal retractions, diffuse crackles on auscul-
tation and hypoxemia on room air. Infection workup
was negative. Bronchoscopy showed no airway anomal-
ies but lipid-laden alveolar macrophages were seen on
BAL fluid examination, indicating chronic tracheal aspi-
rations. CT scan showed widespread ground glass opaci-
ties and multiple subpleural and intraparenchymal cystic
areas predominantly in the upper lobes. The infant
continued oxygen and steroids at higher dosage, but a
repeat chest CT at 18 months showed more extensive
anomalies. An open lung biopsy was then performed,
and showed thickened interstitium with inflammatory
cells and fibrosis, alveolar type II cell hyperplasia, and
cellular and amorphous material in alveolar lumen, a
picture consistent with desquamative interstitial pneu-
monia (DIP), suggestive of genetic surfactant disorders.
SFTPC gene sequencing revealed a mono-allelic I73T
mutation. Parents declined genetic testing. The infant
was discharged with monthly methylprednisolone pulse
therapy plus oxygen. Despite an initial improvement, the
repeat chest CT after 10 pulses showed progression of
ILD. At that stage, HCQ was added to methylpredniso-
lone. After 6 months we observed an improvement in
SaO2/CO2 nocturnal monitoring, allowing weaning then
discontinuation of oxygen therapy and switching to
hydrocortisone as a lower potency steroid regimen. At
the age of 36 months, since chest CT was stable com-
pared to the previous one, HCQ was replaced by
azithromycin given its better safety profile. At 4 years of
age, chest CT was unchanged and the infant was stable
off oxygen and steroids.
Case #3, male, born at term with no neonatal issues.
Family history was unremarkable. The infant had several
episodes of lower respiratory tract infections starting at
2 months of age. At one year of age, he was hospitalized
in the pediatric intensive care unit for acute respiratory
failure, intubated and ventilated. Cystic fibrosis and im-
munodeficiency were excluded. Chest radiography
showed diffuse opacities of both lung fields and intersti-
tial thickening. Lung CT showed multiple ground-glass
consolidations, and thickening of the bronchial vessels.
He underwent a lung biopsy, which showed DIP. Immu-
nohistochemistry showed marked proSP-C accumulation
in hyperplastic type 2 cells and in alveolar macrophages.
Electron microscopy documented abnormal type II
pneumocytes with numerous large cytoplasmic vesicles
(endosomes) filled with unstructured phospholipids,
consistent with SP-C deficiency [5, 10]. Molecular ana-
lysis identified an I73T mutation, inherited from mother
who is an asymptomatic carrier. HCQ was added to ste-
roids after the report of the biopsy but the patient died
after 18 days of intractable respiratory failure.
ILD in infants have a wide range of etiologies includ-
ing genetic abnormalities of the surfactant system, im-
munological defects, environmental exposures and
idiopathic entities such as neuroendocrine cell hyperpla-
sia of infancy and pulmonary interstitial glycogenosis
[11]. These three cases illustrate the variability of clinical
severity associated with the I73T mutation: one asymp-
tomatic at 3 years, one with chronic lung disease at 4,
and one who died at 1. Similar phenotypic variability
was described in a single Mauritanian family affected with
I73T, where 5 affected subjects had very different onset,
symptoms, radiological presentation and outcomes [12].
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The underlying mechanisms of this variable penetrance
are not fully understood.
Trans-heterozygosity has been reported as a molecular
mechanism explaining this expression variability. In a re-
cently published report, three infants with SP-C defi-
ciency due to an I73T mutation and unusually early
respiratory symptoms carried an additional mutation in
the ATP binding cassette protein A3 gene (ABCA3), a
phospholipid carrier essential for lamellar body forma-
tion and surfactant intracellular assembly. ABCA3 defi-
ciency, which typically leads to lethal neonatal-onset
respiratory distress syndrome, is transmitted in auto-
somal recessive mode and heterozygous carriers are un-
affected [13]. However, this report suggests that mono-
allelic mutations in different genes, which would be
asymptomatic if isolated, may inflict multiple hits may
have cumulative effects on the surfactant synthesis path-
way and modify the disease course. We screened the 3
patients in this report for mutations in the SFTPB,
ABCA3 and NKX2.1 genes, all associated with lung dis-
ease in human, and none were found.
There are several lines of evidence that respiratory in-
fection, particularly RSV, can trigger severe lung injury
and catastrophic respiratory failure in SP-C mutation
carriers. Genetically modified animal overexpressing a
common human mutant pro-SP-C (Δexon4, a BRICHOS
domain mutation) show an increased rate of alveolar cell
death [14]. SP-C deficient mice exposed to RSV have a
stronger inflammatory response and more severe inter-
stitial lung disease than controls, and restoration of SP-
C expression by transgene therapy has a rescue effect in
these animals, which could pave the way to future gene
therapy in human [15, 16]. SP-C mutations result in loss
of TLR3 modulation, IL-8 induction and paracrine
modulation of the CCR2 and CXCR1 chemokine recep-
tors on leukocytes leading to uncontrolled inflammation
and fibroblast proliferation. In a recent clinical study by
our group, 4 out of 7 cases were revealed by an un-
usually severe/protracted bronchiolitis episode, and simi-
lar observation was reported by others [5, 7]. In this
report, cases #2 and 3 confirm this concept.
There have been no controlled trials of any treatment
in children ILD and the management is based upon un-
controlled studies, case series, case reports and unsys-
tematic observations. Steroids, hydroxychloroquine and
azithromycin are commonly used in SP-C-related ILD.
Azithromycin has anti-amyloid properties, and hydroxy-
chloroquine affects intracellular proSP-C processing;
hence these drugs may possibly have selective effects on
specific mutations, although there are currently no clin-
ical data available to support this concept. Lung trans-
plantation is an option for children with end-stage ILD,
but its use is limited by donor availability and poor
outcomes [11, 17, 18].
The broader availability of genetic testing has made
early, noninvasive diagnosis accessible to clinicians. CT
findings were consistent with ILD in the three patients,
consistently with recent literature [19]. With proper
technique, chest CT imaging patterns may sufficiently
suggest a diagnosis so as to avoid the need for surgical
lung biopsy. Chest CT is also useful in monitoring the
effects of treatment, as there is a strong correlation be-
tween clinical improvement and CT findings trend: as
previously described, even in our patients 1 and 2,
clinical improvement and weaning-off oxygen were asso-
ciated with a reduction of ground glass opacities.
When lung biopsy is needed, chest CT is important in
guiding the selection of biopsy sites. Surgical lung biopsy
using video-assisted thoracoscopy (VATS) is recom-
mended for infants with clinical urgency to identify the
specific form of ILD or in whom other diagnostic evalu-
ations have not yielded a specific diagnosis. Lung biopsy
specimens should be handled according to established
protocols, with sections available for histopathology,
immunohistochemistry, microbiologic culture, electron
microscopy, immunofluorescence or other special stud-
ies, in consultation with a pediatric pathologist experi-
enced in childhood ILD [13].
Conclusions
This report highlights the importance of screening for
SFTPC mutation in children with ILD of unknown eti-
ology. The clinical variability associated to the I73T mu-
tation demonstrates the importance of disease-modifying
such as respiratory tract infection, particularly RSV. In-
fants with SP-C mutations should benefit from early
prophylaxis measures, such as palivizumab. There is a
great need for multicenter randomized controlled trials
in order to determine the best regimens for existing
drugs that seem to improve the course of the disease, as
well as additional basic and translational research to
identify and test newer agents that improve long-term
prognosis.
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